Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Carna Biosciences Inc lowers full-year consolidated outlook for FY 2013


Friday, 20 Dec 2013 01:30am EST 

Carna Biosciences Inc:Sees lowered full-year consolidated outlook for fiscal year ending Dec. 31, 2013.Sees full-year revenue of 760 million yen lowered from 1,155 million yen.Sees full-year operating profit (loss) of (306 million) yen lowered from 4 million yen.Sees full-year ordinary profit (loss) of (286 million) yen lowered from 28 million yen.Sees full-year net profit (loss) of (290 million) yen lowered from 23 million yen.Sees full-year earnings (loss) per share of (3,768.37) yen lowered from 316.20 yen.Says outlook lowered due to delay in signing of contract with for drug development and sales cost of subsidiary ProbeX. 

Company Quote

891.0
-9.0 -1.00%
18 Sep 2014